Clinical data from a 16-patient pediatric study demonstrate the safety and efficacy of Asceniv in younger populations, ...

The approval is supported by bioequivalence data assessing the once-daily extended-release formulation to twice-daily immediate-release ruxolitinib in healthy participants.

AASM recommends against use of combination of CBT-I plus medication over CBT-I alone for chronic insomnia disorder.

Patients treated with dilanubicel demonstrated faster hematopoietic recovery and had a markedly lower incidence of severe acute GVHD. HealthDay News — Adding dilanubicel, a cryopreserved, cord blood ...

Nereus ™ (tradipitant) is now available for the prevention of vomiting induced by motion in adults. According to manufacturer Vanda Pharmaceuticals, the product is available by ...

Despite earlier antibiotic exposure being more common in those with celiac disease, researcher says 'the connections are much more complex' ...

Radiomics-based early detection model surpasses radiologists for detecting PDA at visually occult prediagnostic stage.

The newly approved oral formulation features a smaller pill size in 1.5mg, 4mg, and 9mg strengths while maintaining the efficacy and safety profile of the previous oral semaglutide version.

HealthDay News — Dietary and lifestyle modifications are reasonable first-line therapies for symptomatic hemorrhoids, according to a clinical practice update issued by the American Gastroenterological ...

Novo Nordisk submitted a BLA to the Food and Drug Administration for denecimig for the treatment of hemophilia A in September 2025.

However, most patients report preferring LAI-ART administered monthly or once every 2 months vs daily oral ART.

The Food and Drug Administration (FDA) has approved Auvelity ® (dextromethorphan HBr and bupropion HCl) for the treatment of agitation associated with dementia due to Alzheimer d ...